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Abstract
Background: Glucocorticoids (GCs) are widely used anti-inflammatory drugs. While useful in
clinical practice, patients taking GCs often suffer from skeletal side effects including growth
retardation in children and adolescents, and decreased bone quality in adults. On a physiological
level, GCs have been implicated in the regulation of chondrogenesis and osteoblast differentiation,
as well as maintaining homeostasis in cartilage and bone. We identified the glucocorticoid receptor
(GR) as a potential regulator of chondrocyte hypertrophy in a microarray screen of primary limb
bud mesenchyme micromass cultures. Some targets of GC regulation in chondrogenesis are
known, but the global effects of pharmacological GC doses on chondrocyte gene expression have
not been comprehensively evaluated.
Results: This study systematically identifies a spectrum of GC target genes in embryonic growth
plate chondrocytes treated with a synthetic GR agonist, dexamethasone (DEX), at 6 and 24 hrs.
Conventional analysis of this data set and gene set enrichment analysis (GSEA) was performed.
Transcripts associated with metabolism were enriched in the DEX condition along with
extracellular matrix genes. In contrast, a subset of growth factors and cytokines were negatively
correlated with DEX treatment. Comparing DEX-induced gene expression data to developmental
changes in gene expression in micromass cultures revealed an additional layer of complexity in
which DEX maintains the expression of certain chondrocyte marker genes while inhibiting factors
that promote vascularization and ultimately ossification of the cartilaginous template.
Conclusion: Together, these results provide insight into the mechanisms and major molecular
classes functioning downstream of DEX in primary chondrocytes. In addition, comparison of our
data with microarray studies of DEX treatment in other cell types demonstrated that the majority
of DEX effects are tissue-specific. This study provides novel insights into the effects of
pharmacological GC on chondrocyte gene transcription and establishes the foundation for
subsequent functional studies.
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Background
Cartilage provides a scaffold for the deposition of osteob-
last precursors and ultimately the development of long
bones. This process, termed endochondral ossification,
describes a coordinated developmental series that
involves commitment of mesenchymal precursor cells to
the chondrogenic lineage and subsequent alternating
phases of proliferation and differentiation, which culmi-
nate in the replacement of the cartilage by bone tissue [1-
4]. In the first phase of this process, multipotent mesen-
chymal progenitors condense and initiate expression of
the pro-chondrogenic Sox family members 9, 5 and 6
[5,6]. A subset of cells at the center of these aggregates dif-
ferentiates into chondrocytes. Newly formed chondro-
cytes secrete an extracellular matrix rich in type II collagen
(Col2a1), proliferate and ultimately terminally differenti-
ate into hypertrophic chondrocytes [7]. Chondrocyte
hypertrophy precedes the end of the chondrocyte life cycle
by apoptosis and is accompanied by vascularization of the
hypertrophic template and mineralization of the cartilag-
inous extracellular matrix [8-12]. Concomitantly, osteo-
clasts degrade the calcified cartilage extracellular matrix,
making way for the invasion and deposition of an osteo-
progenitor population that form the primary ossification
center [13].
These events take place in a region called the growth plate
that illustrates the organization of different phases of car-
tilage development into distinct zones. The resting zone
delineates newly differentiated chondrocytes with low
mitotic activity and the cellular reserve for subsequent
stages of chondrocyte differentiation. Proliferative zone
chondrocytes exhibit higher mitotic activity resulting in
distinct columns containing cells reminiscent of stacked
coins. The hypertrophic zone demarcates terminally dif-
ferentiated chondrocytes which are identified by high
cytoplasm to nuclear ratio and the expression of type X
collagen (Col10a1) [14-16]. Terminally differentiated
chondrocytes are fated for programmed cell death after
which primary ossification occurs by way of vasculariza-
tion of the remaining cartilaginous matrix and the depo-
sition of osteoprogenitor cells [17-19].
Glucocorticoids (GC) are among various endocrine mole-
cules including growth hormone (GH) and thyroid hor-
mone (TH) known to regulate linear growth [20-23].
Regulation of linear growth follows the paradigm in
which steroid hormones affect target tissue through both
local and systemic mechanisms [24-27]. Indirect effects
occur through modulation of other endocrine systems
such as the GH/IGF-I axis. Generally, GC decrease IGF-I,
GH receptor and IGF receptor 1 expression and also abro-
gate the release of GH from the pituitary [20,28,29].
Direct regulation of growth occurs through GC receptor
(GR)-mediated gene transcription in chondrocytes
[24,30,31].
GC functions are primarily mediated by the glucocorti-
coid receptor (GR) that is encoded by the Nr3c1 gene. The
GR is ubiquitously expressed in mammalian tissues,
including the growth plate, and is essential for life [31-
36]. Many studies have examined GC regulation of the
skeleton and have led to various theories on potential
modes of GC function in cartilage [37-40]. The specific
function of the receptor in terms of its transcriptional reg-
ulation in cartilage, however, remains enigmatic.
While endogenous GCs have been shown to promote the
differentiation of both chondrocytes and osteoblasts,
exogenous GCs in pharmacological doses which are also
widely used in clinical practice to treat inflammatory dis-
orders [41-46]. Their have different effects. Indeed, their
utility in treating various diseases is, however, limited by
numerous side effects such as growth failure and
decreased bone quality [47]. GC-target genes including C-
type natriuretic peptide and VEGF have been identified in
chondrocytes [28,48,49]; however, the cartilage-specific
transcriptional consequences of high-GC-doses in the
growth plate have not been studied comprehensively.
Work in our laboratory identified GR amongst factors that
were up-regulated during chondrocyte maturation [50]
Thus, to comprehensively understand the transcriptional
effects of pharmacological GC doses in growth plate, we
completed a genomic screen of gene expression changes
in chondrocytes derived from E15.5 day old mouse
embryos. Primary monolayer chondrocytes were treated
with a synthetic GC, dexamethasone (DEX), and RNA was
isolated for microarray analysis. We complemented tradi-
tional microarray analysis methods with the gene set
enrichment algorithm to correlate the behaviour of spe-
cific molecular classes with DEX treatment [51,52].
Results and Discussion
Microarray screen of dexamethasone-treated primary 
chondrocyte monolayers
We identified the GR as a candidate for the regulation of
chondrocyte hypertrophy in a previous expression profil-
ing screen using primary micromass cultures [50]. The
Nr3c1 probe set which encodes the GR was up-regulated
4-fold from day 3 to day 15 of micromass culture (Figure
1A, top panel). Confirmation of the GR expression profile
with qRT-PCR showed an approximately 8-fold increase
over the same time course (Figure 1A, bottom panel).
Studies in our laboratory and others have implicated GCs
in chondrocyte differentiation and growth plate function
[25,26,47,48,53,54]. In addition, our cell counting exper-
iments revealed that DEX consistently decreases cell num-
bers after 24 hrs (Figure 1B), in agreement with otherBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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studies that show increased apoptosis [38,55] and
reduced proliferation [56] in response to GCs. We there-
fore aimed at extending this analysis to examine pharma-
cological effects of GCs on growth plate chondrocytes by
systematically identifying downstream effector genes of
DEX. Primary chondrocytes derived from the long bones
of 15.5 day old embryonic mice were treated with DEX or
the vehicle control, and total RNA was isolated after 6 and
24 hrs of culture, respectively.
Gene expression was evaluated using Affymetrix MOE 430
2.0 mouse genome chips using three independent cell iso-
lations. We first analyzed gene expression using conven-
tional analysis functions in GeneSpring GX*. After pre-
processing the data set using the GC-RMA algorithm and
eliminating probe sets showing expression levels close to
background, 22 091 probe sets remained, reducing the
data set by 48% (Table 1). Significance testing with one-
Way ANOVA analysis identified probe sets differentially
expressed between DEX and vehicle-treated cultures over
the entire time course (Figure 1C, left panel). The resulting
list contained 1158 probe sets, which is 2% of the data
set's original size. Approximately 70% of significantly
changed probe sets exhibited upregulation in response to
DEX treatment. This data set was further subdivided by
using 1.5-, 5- and 10- fold change filters which generated
lists of 162, 21 and 7 probe sets for the 6 hr time point and
399, 53 and 19 probe sets for the 24 hr time point, respec-
tively (Table 1). Examination of the overall differences
between the mean normalized signal intensities associ-
ated with each condition showed minimal changes in
gene expression (Figure 1C, right panel), indicating that
GC treatment affects the expression of only a small subset
of all expressed genes in this system. A distribution of fold
differences between 6 and 24 hrs showed that the majority
of gene expression changes did not exceed 2-fold (Figure
1D). In each case, both time points exhibited the same
overall trends in gene expression, but, as expected, the 24
hr time point consistently showed a higher proportion of
probe sets altered by DEX treatment.
Probe set validation
To confirm the accuracy of the microarrays in identifying
biologically significant differences, we selected a variety of
expressed transcripts for qRT-PCR analysis (Figure 2A).
Transcripts that either belonged to a functional class
implicated in cartilage development or exhibited marked
changes with DEX treatment were chosen. Markers exhib-
iting marginal changes in gene expression were also
selected for control purposes. Specifically, we evaluated
the expression patterns of Indian hedgehog (Ihh), Tissue
inhibitor of matrix metalloproteinase 4 (Timp4), Cyclin-
dependent kinase inhibitor 1C (Cdkn1c), which contains
a GC response element in its promoter [57], Integrin beta
like 1 protein (Itgbl1), GC receptor (Nr3c1), Integrin beta
1 (Itgb1) and Kruppel-like factor 15 (Klf15) over 0, 6, 12,
and 24 hrs of culture with or without DEX treatment.
Transcripts for Klf15 were up-regulated from 0 to 6 hrs
while Ihh, Timp4, Cdkn1c and Itgbl1 all increased after the
6 hr time point. Nr3c1, which encodes the GR, was not
affected by DEX-treatment at both 6 and 24 hrs, but does
contain a putative GRE [58]. Transcripts such as Itgb1 that
exhibited less than 1.5-fold change in our arrays were also
confirmed with qRT-PCR, providing further evidence that
the microarray data represented authentic gene expression
data. Interestingly, the fold change difference varied
according to the experimental method. In cases such as
Timp4 and to a lesser extent Cdkn1c, qtPCR data showed
higher fold change increases with the DEX treatment than
in microarrays. In contrast, the expression pattern for
Klf15  exhibits a higher fold-change difference in the
microarrays compared to the control. While data normal-
ization using the RMA algorithm provides excellent esti-
mates of reliable signal intensities, other methods such as
the M.A.S. 5.0 algorithm are known to outperform RMA
in its ability to accurately estimate fold change differences
in transcript levels [59].
GSEA to identify the effects of dexamethasone on gene 
expression in chondrocytes
Traditional microarray analysis methods are useful for the
identification of probe sets exhibiting transcriptional
responses to DEX-treatment, but are limited in certain
capacities. Alternate statistical methods such as ANOVA
testing produced transcript lists that, while effectively
reducing the dimensionality or sample size of the data set,
increased the rate of false negative data thus hampering
our ability to generate meaningful hypotheses from the
data (Figure 1). Also, the overall effect of DEX treatment
on gene expression was modest, which may have reduced
the significance of biologically relevant genes because
their signal intensities were close to background levels.
Accordingly, we did not have a clear concept of the central
pathways and biological categories affected by DEX treat-
ment. Similarly, Gene Ontology annotations were not suf-
ficiently robust to detect differences in the representation
of specific molecular categories (data not shown). We
therefore implemented GSEA [52], an algorithm that is
designed to effectively evaluate the effect of a specific
experimental condition on known biological pathways
and functional categories. These analyses show whether a
given treatment (e.g. DEX stimulation) results in enrich-
ment of genes sets involved in the regulation of a specific
phenotype (see materials and methods for details).
We created a gene set consisting of 77 gene lists represent-
ing different tissue types, functional categories and path-
ways derived from other microarray studies in the
literature (Table 2). We drew conclusions from the top
gene sets that had a false discovery rate (FDR) less thanBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Gene expression changes in DEX-treated primary chondrocytes Figure 1
Gene expression changes in DEX-treated primary chondrocytes. Microarray and quantitative RT-PCR expression 
profiles of the Glucocorticoid receptor (Nr3c1) in primary mesenchymal micromass cultures (A). Primary chondrocytes are 
plated in high density monolayers and treated with DEX or vehicle for 24 hrs and counted with a hemocytometer (B). Ordered 
list of global microarray data set derived from the hybridization of RNA isolated from primary chondrocytes treated with 10-7 
M DEX and the vehicle (v) control (C, left panel). One-Way ANOVA testing for significantly expressed probe sets between 
DEX-treated samples and the vehicle control resulted in a list of 1158 transcripts. Mean normalized signal intensities for all 
1158 probe sets are shown (C, right panel). Fold change filtering of these transcripts reveal that the majority of probe sets vary 
in the range of 1 to 2-fold (D).
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25% and a p-value less than 0.001, both of which are
acceptable cut-offs for the identification of biologically
relevant probe sets. This cut-off, although relatively high,
was optimized to reduce the occurrence of false negative
data in data sets interrogating a small number of gene sets.
Additionally, the FDR compensates for the inherent lack
of coherence microarray data sets exhibit between gene
expression and specific experimental conditions [52].
Enriched gene sets were identified in both DEX and vehi-
cle data (Table 3). Specifically, the highest statistical con-
fidence and correlation with the DEX phenotype was
assigned to metabolism and extracellular matrix, which
contained 196 and 228 genes, respectively (Figure 3, left
panels, Table 4 and 5). In each case, the expression of
genes positively correlated with the DEX phenotype at the
24 hr time point exceeded the number of genes at the 6 hr
time point (Figure 3, right panels). Metabolic genes
included aldehyde and alcohol dehydrogenases (Table 4),
among others, and were identified in accordance with pre-
viously documented roles for GC in various metabolic
processes and tissues [60,61]. Closer examination of the
genes contributing to the enrichment scores for the ECM
gene set revealed that Dentin matrix protein 1 (Dmp1) was
the top ranking gene (Table 5). DMP1 belongs to the SIB-
LING family of matrix molecules and has been linked to
chondrocyte differentiation. Dmp1 knockout mice display
disordered postnatal chondrogenesis, among other skele-
tal abnormalities [62]. Interestingly, integrin binding sia-
loprotein (Ibsp) [63-66]), another SIBLING family
member, and osteocalcin (Bglap2) both contain putative
GRE sequences, but did not contribute to the enrichment
score for this category [63,66]. They did, however, belong
to the core group of genes that were enriched when a
micromass culture gene set was used to interrogate the
DEX data (Figure 4).
Osteomodulin, an additional matrix molecule shown to
be structurally similar to IBSP [67], ranked second in the
list of enriched ECM genes. Additional ECM molecules
expressed in terminally differentiated chondrocytes such
as collagen 10 (Col10a1) and osteonectin (Spock1) were
identified, suggesting that this molecular classification is
important for transmitting GC signaling in the growth
plate.
Interestingly, the normalized enrichment scores for fac-
tors down-regulated by DEX treatment were higher than
those positively correlated with DEX, but contained fewer
probe sets contributing to the scores. Gene sets composed
of 127 and 106 genes associated with cytokine and growth
factor activity, respectively, were negatively correlated
with DEX treatment (Figure 4, Table 6, 7). In other stud-
ies, cytokines such as Il-8 and GROα were found to pro-
mote the hypertrophy of osteoarthritic cartilage, and
excess interleukins 1β(IL-1β), interleukin 6 (IL-6) and
Tumor Necrosis Factor alpha (TNF-α) cause growth fail-
ure in children [68-70]. Our studies identified three mem-
bers of the GP-130 family of cytokines, namely
interleukins -11,-6 (Il11, Il6) and leukemia inhibitory fac-
tor (Lif), as part of the core enrichment group for
cytokines (Table 6). Transgenic mice overexpressing Il-6
exhibit growth retardation, and LIF is thought to regulate
the rate at which terminally differentiated cartilage is cal-
cified and vascularized [71,72].
This group also contained the gene encoding Tumor
necrosis factor (ligand) superfamily, member 11 (Tnfsf11,
RANKL), which has been localized to mature chondro-
cytes and is thought to promote degradation of the calci-
fied cartilage ECM and ultimately endochondral
ossification through activation of osteoclasts [73-75]. It is
important to note that several independent gene sets con-
nected to inflammation such as cytokines, chemokines
and interleukins exhibit some overlap and showed similar
enrichment patterns, which provides additional confir-
mation that DEX is indeed downregulating inflammatory
molecules in chondrocytes. GC have been previously
reported to down-regulate the expression of VEGF, one of
Table 1: Microarray analysis of DEX-treated primary chondrocyte monolayers.
Specifications Probe sets at 6 hrs Probe sets at 24 hrs
Total number of probe sets 45101 45101
Significantly expressed 22091 22091
Differentially expressed 1158 1158
1.5-fold changed 162 399
5-fold changed 21 53
10-fold changed 7 33
1.5-fold up-regulated 141 342
5-fold up-regulated 20 50
10-fold up-regulated 7 19
1.5-fold down-regulated 21 57
5-fold down-regulated 1 3
10-fold down-regulated 0 0BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Identification of significantly expressed probe sets and subsequent validation with real-time RT-PCR Figure 2
Identification of significantly expressed probe sets and subsequent validation with real-time RT-PCR. Expression 
profiles for selected transcripts in vehicle- or DEX-treated chondrocytes are confirmed with real-time RT-PCR at 0, 6, 12 and 
24 hr time points. Indian hedgehog (Ihh), tissue inhibitor of matrix metalloproteinase 4 (Timp4), cyclin-dependent kinase inhibi-
tor 1C (Cdkn1c, p57), integrin beta like 1 protein (Itgbl1), glucocorticoid receptor (Nr3c1), integrin beta 1 (Itgb1) and kruppel-
like factor 15 (Klf15) microarray data are shown on the left at the 6 and 24 hr time points and corresponding real-time expres-
sion values are shown on the right. P-values less than 0.01 are deemed significant. Specifically, Ihh, Timp4, Itgbl1 and Klf15 
exhibit significant differences between the 6 and 24 hr time point and between treatments. Dotted lines indicate the control 
and solid lines denote DEX treatment.





































5HDOWLPH3&5H[SUHVVLRQSURILOH
,KK
7LPS
&GNQF
,WJEO
1UF
,WJE
.OI
   
KRXUV
0LFURDUUD\H[SUHVVLRQSURILOH











7LPS







,KK










1UF
,WJE
.OI






&GNQF



 ,WJEO
 
KRXUV
,KK
Q
R
L
V
V
H
U
S
[
(

Q
L

H
J
Q
D
K
&

G
O
R
)
Q
R
L
V
V
H
U
S
[
(

Q
L

H
J
Q
D
K
&

G
O
R
)BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
Page 7 of 27
(page number not for citation purposes)
the central growth factors involved in vascularization of
calcified cartilage matrix [49], in agreement with our data
(Table 7). Since some of these factors, such as RANKL,
VEGF and LIF, promote normal tissue remodeling proc-
esses during endochondral ossification, our data suggest
that DEX prevents the replacement of hypertrophic carti-
lage by bone. GC have been shown to delay chondrocyte
maturation while retaining their capacity to re-engage in
their developmental program [21]. This could account for
upregulation of genes typically associated with the
chondrocyte phenotype, such as ECM genes and the coor-
dinated downregulation of factors that promote the tran-
sition from cartilage into bone.
Identification of cartilage-specific dexamethasone-effects
Identification of cartilage-specific gene sets affected by
DEX treatment provided further insight into the complex
nature of GC functions in cartilage. We knew from other
studies that DEX effects on chondrogenic differentiation
are dependent on cell source, experimental system and
DEX concentration [40,42,76-78]. We aimed to systemat-
ically characterize the effects of DEX on growth plate
chondrocytes. To ensure that our DEX data set was
expressing bona fide cartilage markers, we compared the
DEX data to our previously generated micromass culture
data set [50]. We compared all expressed probe sets in the
DEX array to probe sets exhibiting a minimum 1.5-fold
Table 2: Gene sets used in GSEA.
Category name Number of genes Category name Number of genes
Adipose 70 Nucleus_3 510
A p o p t o s i s 3 9F k b p3 3
Bone 116 3vs15_1.5x_1 497
Cartilage 28 3vs15_1.5x_2 497
Catalytic 245 3vs15_1.5x_3 497
Chaperone 81 3vs15_1.5x_4 497
Chemokine 31 3vs15_1.5x_5 76
Chromatin/Hdacs 24 Igf 48
Cyclin 225 Cart_2 299
Cytokine 127 Cart_3 352
1_Dnabind 500 Liver_1 260
2_Dnabind 448 Liver_2 260
Ecm 228 Blood 111
Electron_Transp 40 Protease_1 269
Gf Receptor 327 Protease_2 269
Gluconeogen 31 Phosphatase 473
Growth Factor 106 Dusp 20
Gtpase Activator 46 Kinase_1 499
Gtpase Activ 73 Kinase_2 499
Heparin Bind 37 Kinase_3 227
Hormone 75 Integrin_Rel 173
Muscle 198 Brain_Rel 379
Neg_Apoptosis 50 Hepatocyte 19
Oncogene 154 Obl_Oclast 16
Pos_Apoptosis 79 Interleukinrelated 175
Related_Apoptosis 311 Rgs_Related 44
Structure 151 Caspase_Related 47
Sugar_Bind 104 Creb_Atf3 32
Tf_Activ 56 Nuclear Receptor 138
Tf_Repress 55 Nuc_Hormone_Receptor 55
Tgfb 45 Mapkrelated 267
Tnf_Receptor 69 Membrane 260
Tumor Suppressor 48 Metabolism 196
Wnt 53 Nucleus_1 494
Actin_Cytoskel 38 Nucleus_2 494
Angiogen 57 Pzhorton.Farnum 413
Bmprelated 62 Hzhorton.Farnum 407
Cytoplasm 411
Erk_Related 40
Fgf_Related 64BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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change in expression between days 3 and 15 of micromass
cultures that encompass the various stages of the chondro-
cyte life cycle. Day 3 of micromass culture likely coincides
with the onset of the cartilage developmental program
and early chondrogenesis. After 15 days of culture, the cell
population is comprised primarily of terminally differen-
tiated chondrocytes and thus corresponds mostly to the
hypertrophic zone of the growth plate [50,79], although
small numbers of other cells are present at all stages. Out
of the 2119 probe sets displaying at least 1.5-fold changes
in expression in the micromass culture data set (a probe
set list generated from the pair-wise comparison of day 3
versus day 15 of micromass culture), 1730 were also
expressed in the DEX array. This shows that our primary
chondrocyte monolayers do exhibit prototypical
chondrocyte gene expression patterns in both the pres-
ence and absence of DEX treatment.
To complete more robust classification of the data in
which we could correlate chondrocyte gene expression to
the DEX phenotype, we created a gene set from this list of
2119 probe sets (Table 8, 9). The micromass derived gene
list was enriched in this study; however, the list was found
to correlate both positively and negatively with different
aspects of the DEX phenotype. We therefore proceeded to
evaluate both the micromass (MM) data set and the DEX
data set using GSEA analysis and the previously created
gene sets. If both the micromass time course and the DEX
data sets show the same enrichment pattern, we would
have evidence to suggest that pharmacological DEX doses
promote chondrocyte differentiation. Normalized enrich-
ment scores for gene sets common to both culture meth-
ods were therefore compared to identify differences and
similarities between DEX-treated chondrocytes and the
chondrocyte phenotype (Figure 4B).
Table 3: GSEA of DEX-treated primary chondrocytes.
Gene set name Size ES NES NOM p-val FDR q-val
Metabolism 196 0.471 1.935 <0.001 0.016
Extracellualr Matrix 228 0.451 1.878 <0.001 0.016
Fkbp 33 0.559 1.696 0.011 0.054
Integrin_Related 173 0.407 1.643 <0.001 0.001
Angiogenesis 57 0.4791 . 6 1 00 . 0 1 20 . 0 6 5
Kinase_1 499 0.343 1.549 <0.001 0.092
Tumor Suppressor 48 0.457 1.492 0.037 0.126
Catalytic 245 0.337 1.420 0.008 0.172
Hepatocyte 19 0.529 1.406 0.104 0.161
D3 Vs D15_2 497 0.304 1.368 0.004 0.194
Igf 48 0.412 1.348 0.093 0.208
Cyclin 224 0.322 1.344 0.028 0.199
Actin_Cytoskel 38 0.426 1.325 0.124 0.213
Structure 151 0.3321 . 3 1 20 . 0 5 30 . 2 1 9
Cytoplasm 411 0.292 1.300 0.023 0.224
Adipose 70 0.368 1.285 0.116 0.232
Gtpase Activity 73 0.363 1.280 0.113 0.230
Cartilage 28 0.432 1.262 0.169 0.246
Chemokine 31 -0.779 -2.40 <0.001 0
Cytokine 127 -0.579 -2.31 <0.001 0
Growth Factor 106 -0.517 -2.01 <0.001 7.698E-04
Interleukinrelated 175 -0.469 -1.98 <0.001 9.475E-04
Bone 16 -0.577 -1.51 0.051 8.945E-02
Creb_Atf3 30 -0.469 -1.43 0.065 1.300E-01
Dusp 20 -0.508 -1.40 0.102 1.418E-01
Blood 111 -0.351 -1.37 0.037 1.425E-01
3vs15_1.5x_3 496 -0.288 -1.35 0.002 1.518E-01
Protease_2 268 -0.306 -1.35 0.015 1.411E-01
Nuc_Hormone_Rece
ptor
55 -0.381 -1.32 0.086 1.570E-01
Tf_Repress 55 -0.380 -1.32 0.091 1.498E-01
3vs15_1.5x_4 497 -0.272 -1.28 0.011 1.817E-01
Erk_Related 40 -0.385 -1.25 0.157 2.169E-01
ES, enrichment score
NES, normalized enrichment score
FDR q-val, false discovery rate and multiple testing corrections (q-value)
NOM p-val; the uncorrected p-valueBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
Page 9 of 27
(page number not for citation purposes)
Four different patterns were observed when comparing
DEX treatment and micromass differentiation data sets for
gene enrichments scores (Figure 4B). First, similar gene
sets were indeed enriched in both day 15 micromass and
DEX-treated monolayer cultures, and core genes contrib-
uting to the normalized enrichment scores were similarly
overlapping between the two data sets in results with low
FDR. For example, ECM genes were enriched with both
DEX treatment and the day 15 micromass phenotype.
Other gene sets following this enrichment pattern
included genes involved in integrin function, angiogen-
esis, catalytic activity, IGF related, adipocyte and cartilage,
all of which have a precedent for being involved in
chondrocyte maturation [28,49,80,81]. The enrichment
of angiogenic transcripts with DEX treatment was unex-
pected since DEX was shown to have anti-angiogenic roles
in cartilage; however, upon closer examination of the
genes contributing to the enrichment score, Vegf, which is
thought to be a central angiogenic factor in endochondral
ossification [82], was excluded from the core enrichment
genes and had the lowest correlation with the DEX pheno-
type in that gene set. In contrast, Vegf was enriched in the
growth factor data set which positively correlated with the
vehicle control and not DEX treatment (Table 7).
Gene sets associated with the actin cytoskeleton, tumour
suppressors, structure, cytoplasmic genes, hepatocyte
markers and dual specificity phosphatases (DUSPs) were
enriched in the DEX data set and the phenotype positively
correlated with day 3 of micromass culture. The identifica-
tion of DUSPs was particularly interesting since DEX has
been shown to induce genes encoding for these proteins
[77,83,84]. DUSPS counteract the activation of MAP
kinase pathways, known regulators of chondrocyte differ-
Table 4: Metabolic transcripts enriched in DEX-treated chondrocytes. I.
HUGO symbol Rank RMS* RES** HUGO symbol Rank RMS* RES**
Aldh1a1 26 0.417 0.053 Slc27a4 1616 0.058 0.426
Eya2 40 0.355 0.099 Ltbp2 1721 0.056 0.428
Vcl 106 0.228 0.125 Hsd17b1 1783 0.055 0.432
Adhfe1 116 0.222 0.154 P4ha2 1783 0.055 0.432
Ids 123 0.212 0.181 Mut 1850 0.053 0.443
Cbr3 133 0.204 0.207 Pde3a 2195 0.048 0.432
Aldh6a1 202 0.165 0.225 Sulf2 2200 0.048 0.438
Bcat2 224 0.157 0.245 Prep 2316 0.046 0.438
Pmm1 278 0.145 0.261 Plod3 2387 0.045 0.441
Pcx 553 0.105 0.261 1110013G13RI
K
2510 0.043 0.440
Fthfd 554 0.105 0.275 Pld1 2669 0.041 0.437
Atp1a1 560 0.104 0.288 Au041707 2721 0.040 0.440
Gstm1 619 0.099 0.298 Decr1 2837 0.039 0.439
Gstm2 742 0.088 0.303 Gstm5 2872 0.038 0.443
1700061G19RI
K
787 0.086 0.312 Bckdha 2932 0.038 0.445
Slc38a4 833 0.084 0.321 Atp11a 2951 0.038 0.449
Pyp 847 0.083 0.331 Gstp1 2967 0.037 0.453
Aacs 901 0.080 0.339 Dhrs7 3014 0.037 0.455
Plod1 934 0.079 0.348 Cbr2 3147 0.035 0.453
Acas2 983 0.077 0.355 Echdc3 3152 0.035 0.458
Auh 1068 0.074 0.361 Acy3 3254 0.035 0.457
Gcat 1109 0.072 0.368 Dhrs1 3483 0.032 0.450
Dhrs8 1184 0.070 0.373 Itgb1 3527 0.032 0.452
Egln3 1232 0.068 0.380 4933406E20RIK 3553 0.031 0.454
Mthfs 1268 0.067 0.387 Plod2 3574 0.031 0.458
Mvk 1298 0.066 0.394 Pmm2 3582 0.031
Aup1 1325 0.065 0.401 Ugp2 3583 0.031
Spr 1456 0.062 0.403 Gnpat 3633 0.031
Sc5dl 1462 0.062 0.411 1110003P22RIK 3636 0.031
1300018J18RIK 1516 0.061 0.416 Dbt 3710 0.030
Agpat3 1524 0.061 0.423
Rank = position of genes in the context of the ranked list of array genes
RMS = the ranked metric score
RES = the running enrichment scoreBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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entiation [85], and are thought to mediate DEX's anti-
inflammatory functions and to influence hepatic glucone-
ogenesis [83,86,87].
Additional comparisons identified genes that show
enrichment in day 15 micromass cultures and downregu-
lation with DEX treatment. These include the previously
identified chemokines, cytokines and interleukins. A final
trend in similarly enriched gene sets identified lists that
were negatively correlated both with the DEX phenotype
and day 15 of micromass cultures. Only transcriptional
repressors and molecules involved in the extracellular sig-
nal-regulated kinase (ERK) pathway were identified. This
pattern is consistent with DEX's anti-proliferative func-
tions, as another study showed that DEX decreases ERK
phosphorylation and thus cell cycle progression in a pre-
osteoblast cell line [77]. Altogether this analysis shows
that DEX regulation of growth plate chondrocyte differen-
tiation is multifaceted. The patterns identified here are in
agreement with a dual role of DEX in maintenance of the
cartilage phenotype and delay in the cartilage-to-bone
transition, as we suggested above.
We also wanted to determine whether DEX target genes
identified in the current study were similar to DEX-
responsive genes identified in alternate studies, in differ-
ent cell types [88]. Out of a total of twelve microarray
studies evaluating the transcriptional effects of DEX treat-
ment on a specific tissue or cell type, only ten genes were
common to at least three of the chosen DEX studies. Spe-
cifically, bone morphogenetic protein 2 (Bmp2), delta
sleep inducing factor 1 (Dsip1), beta-2 microglobulin
(B2m), neuroepithelial cell transforming gene 1 (Net1),
TNFAIP3 interacting protein 1 (Tnip1), bone marrow stro-
mal cell antigen 2 (Bst2), B-cell leukemia/lymphoma 6
(Bcl6), nuclear factor of kappa light chain gene enhancer
in B-cells inhibitor, alpha (Nfkbia), FK506 binding pro-
tein 5 (Fkbp5) and B-cell translocation gene 1, anti-prolif-
erative (Btg1) were identified. It therefore appears that
while DEX affects similar functional categories across var-
ious species, tissue types and experimental conditions, the
individual genes that respond to DEX treatment are varia-
ble. These results also reinforce the paradigm that GC reg-
ulation is inextricably linked to its physiological context
[88-99].
Analyses of GC response elements in dexamethasone 
target genes in chondrocytes
Classical genomic GC action is thought to be mediated by
a cytoplasmic GR that modifies transcription upon bind-
Table 5: ECM-related transcripts enriched in DEX-treated chondrocytes.
HUGO symbol Rank RMS RES HUGO symbol Rank RMS* RES**
Dmp1 18 0.470 0.036 Matn4 882 0.081 0.420
Omd 27 0.409 0.068 Lama3 886 0.081 0.427
Itga5 38 0.358 0.095 Nyx 992 0.077 0.427
Adamts1 57 0.305 0.118 Lamb2 1082 0.073 0.429
Timp4 61 0.296 0.141 Bsg 1100 0.072 0.433
Col4a1 86 0.268 0.161 Fbn2 1242 0.068 0.432
Col4a2 98 0.247 0.180 Ntn4 1245 0.068 0.437
Adam12 112 0.225 0.197 5730577E14RIK 1381 0.064 0.435
Prelp 139 0.200 0.211 Col6a2 1405 0.064 0.439
Postn 142 0.195 0.227 Ntn3 1415 0.063 0.443
Chad 176 0.174 0.239 Tgfb2 1531 0.060 0.442
Mgp 195 0.168 0.251 Mia1 1575 0.059 0.445
Col1a1 232 0.154 0.261 Mmp14 1803 0.054 0.438
Mfap5 233 0.153 0.273 Col15a1 1845 0.053 0.440
Col10a1 266 0.146 0.283 Ctgf 1882 0.052 0.442
Smoc2 279 0.145 0.294 Col6a1 1942 0.052 0.443
Aspn 294 0.141 0.304 Gpld1 1946 0.051 0.447
Col4a5 367 0.128 0.310 Emid2 2043 0.050 0.446
Adamts15 385 0.126 0.319 Col7a1 2047 0.050 0.450
Tgfb1 394 0.125 0.329 Adam10 2107 0.049 0.451
Sparcl1 440 0.119 0.336 Col9a2 605 0.100 0.370
Adam17 483 0.112 0.343 Matn3 610 0.099 0.377
Lama5 508 0.110 0.350 Col11a2 636 0.097 0.384
Lamc1 517 0.109 0.358 Hapln1 650 0.096 0.391
Spock2 581 0.102 0.363 Lama2 685 0.092 0.396
Lama1 688 0.092 0.403 Gpc3 796 0.086 0.412
Ltbp4 704 0.091 0.410 Lama4 827 0.084 0.417
*RMS = the ranked metric score
**RES = the running enrichment scoreBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Enrichment plots for statistically significant gene sets identified by GSEA Figure 3
Enrichment plots for statistically significant gene sets identified by GSEA. User-defined gene sets enriched with the 
DEX or vehicle conditions are depicted. Black bars illustrate the position of probe sets belonging to metabolic, extracellular 
matrix (A), cytokine and growth factor (B) gene sets in the context of all probes on the DEX array. The running enrichment 
score (RES) plotted as a function of the position within the ranked list of array probes is shown in green. The ranked list metric 
shown in gray illustrates the correlation between the signal to noise values of all individually ranked genes according and the 
class labels (experimental conditions). Metabolic and ECM genes are overrepresented in the left side of the enrichment plot 
indicating correlation to differential expression in DEX-treated chondrocytes. In contrast, cytokines and growth factor genes 
are enriched in the right side of the plots and correspond to the vehicle control. Significantly enriched data sets are defined 
according to GSEA default settings i.e., a p < 0.001 and a false discovery rate (FDR) < 0.25. Individual expression profiles for 
probe sets contributing to the normalized enrichment score are shown in the right panel. R.L.M = ranked list metric, E.S. = 
enrichment score.
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Comparison of DEX-treated primary chondrocytes to a time course of chondrocyte differentiation in micromass culture Figure 4
Comparison of DEX-treated primary chondrocytes to a time course of chondrocyte differentiation in micro-
mass culture. The Venn diagram depicts probe sets that are common between the list of 2119 probe sets differentially 
expressed between days 3 and 15 of micromass culture and the list of 22 091 significantly expressed probe sets in primary 
chondrocyte monolayer cultures (A). The matrix of 77 user-defined gene sets are used to interrogate microarray data from 
days 15 and day 3 of micromass culture. Normalized enrichment scores (NES) generated from this analysis are then compared 
to NES scores derived from the DEX study to evaluate similarities in the regulation of different groups of genes in chondro-
cytes (B). Positive enrichment scores (ES) indicate gene sets that are enriched and up-regulated in DEX-treated chondrocytes 
or d15 of micromass culture. Negative ES indicate gene set enrichment and down-regulation in the DEX-treatment or up-reg-
ulation in the day 3 samples of the micromass (MM) culture data set.
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ing its cognate ligand and translocating to the nucleus. In
the nucleus, the GR binds a GRE sequence. GR can both
activate and repress transcription, depending on the GRE
variant present in the regulatory regions of GC target
genes [100]. Binding to composite GREs involves
homodimerization of the GR to bind a non-palindromic
consensus sequence comprised of two GR binding sites
and is generally associated with transcriptional activation.
In some instances, however, GR can function to block
access or activity of transcription factors within promoter
regions of certain genes, thus impeding transcription
[101]. GR are also able to bind a modified GRE consisting
of composite GRE half-sites, termed negative GREs, since
they have documented roles in transcriptional repression.
Variations on the genomic functions of GC include tran-
scriptional regulation at the level of protein-protein inter-
actions between the GR and other transcription factors,
co-activators or co-repressors. In addition to the GRE-
dependent roles, the GR is capable of interacting with
other co-activators and repressors to influence transcrip-
tion indirectly [102,103].
The 100 most highly expressed probe sets with greatest
enrichment in the DEX or vehicle-treated chondrocytes
Table 6: Cytokine transcripts enriched in vehicle-treated chondrocytes. I.
HUGO gene symbol Rank RMS RES
Cklfsf2b 16971 -0.0424 -0.574
Il7 16981 -0.0425 -0.569
Il1f9 17007 -0.0427 -0.566
Grn 17130 -0.0439 -0.567
Il1f6 17153 -0.0442 -0.563
Ifna2 17418 -0.0468 -0.571
Tslp 17503 -0.0477 -0.570
Il17 17568 -0.0483 -0.568
A730028g07rik 17606 -0.0486 -0.564
Cxcl11 17634 -0.0490 -0.560
Ctf1 17857 -0.0519 -0.565
Lta 17864 -0.0519 -0.559
Il1a 18018 -0.0539 -0.561
Ccl20 18038 -0.0542 -0.556
Ccl17 18334 -0.0584 -0.564
Ccl12 18384 -0.0592 -0.560
Cklf 18618 -0.0639 -0.564
Ifna11 18855 -0.0688 -0.568
Cklfsf6 18874 -0.0693 -0.561
Il15 18955 -0.0719 -0.557
Ltb 19146 -0.0779 -0.558
Ccl3 19220 -0.0814 -0.552
Tnfsf9 19228 -0.0816 -0.543
Cx3cl1 19523 -0.0975 -0.547
Gdf15 19660 -0.1100 -0.541
Bmp5 19775 -0.1238 -0.533
Cxcl14 19798 -0.1289 -0.519
Cxcl1 19928 -0.1698 -0.507
Cxcl10 19951 -0.1807 -0.487
Ccl7 19956 -0.1849 -0.466
Gdf5 19973 -0.2066 -0.444
Cxcl12 19978 -0.2104 -0.420
Areg 19983 -0.2189 -0.395
Cxcl2 19996 -0.2421 -0.369
Ppbp 20014 -0.2944 -0.336
Lif 20024 -0.3296 -0.299
Ccl2 20030 -0.3589 -0.258
Il11 20035 -0.4036 -0.213
Cxcl5 20039 -0.5406 -0.152
Tnfsf11 20041 -0.5835 -0.085
Il6 20043 -0.7529
Rank = position of genes in the context of the ranked list of array genes
RMS = the ranked metric score
RES = the running enrichment scoreBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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are shown in Figure 5. Probe sets identified in this analysis
included both known cartilage markers and established
DEX target genes such as Vegf, Ibsp,  Bglap2  and  Fkbp5
[49,63-66,104,105]. We examined the proximal promoter
regions of three separate gene lists, the top 100 DEX-
responsive transcripts generated by GSEA analysis (Figure
5), the 22 091 probe sets deemed expressed in primary
chondrocyte cultures and the 1158 transcripts deemed
differentially expressed between DEX and vehicle treated
cultures by one-Way ANOVA. Specifically, we searched
the 9990 base pairs upstream regulatory regions in this list
for the composite GRE consensus sequence. We identified
putative GRE sequences in many genes, including Fkbp5,
pyruvate dehydrogenasekinase (Pdk4), RANKL (Tnfsf11),
Interleukin 6 (Il6) and prostaglandin I2 synthase (Ptgis)
(bold in Figure 5). However, the majority of DEX-regu-
lated probe sets such as prostaglandin-endoperoxide syn-
thase 2 (Ptgs2), phosphodiesterase 4A (Pde4), Vegf, Period
homolog 1 (Per1) and Krüppel like factor 15 (Klf15) do
not appear to contain a GRE in the first 10 kilobases and
may by regulated by DEX via a GRE-independent mecha-
nism, through a GRE that deviates from the consensus
GRE sequence or through GREs at other locations in the
gene.
Examination of all lists generated similar results in that
approximately 16–20% of all probes contained the con-
sensus GRE. Consequently, we cannot exclude the pres-
ence of less conventional GRE loci in the transcripts, or
the presence of GREs that deviate from the consensus
sequence or are located outside the queried sequence.
Since many of the genes affected at the 6 hr time point
encode transcription factors, it is likely that a large propor-
tion of the genes that only change after 24 hrs are regu-
lated indirectly by DEX, through altered expression of
these transcription factors and other regulatory proteins
(e.g. phosphatases and cytokines, as discussed above).
Functional analysis is required to unequivocally evaluate
the contribution of GRE-dependent mechanisms to GC
regulation in chondrocytes. In addition to the genomic
functions of GC, non-genomic modes of GC regulation
have been documented. Non-genomic mechanisms are
thought to occur through specific and non-specific mech-
anisms. Specific non-genomic GC regulation occurs
through the classical GR and its cytoplasmic heteropro-
tein complex or non-classical GRs such as membrane GR
[106-109]. Conversely, non-specific non-genomic mecha-
nisms rely on the physiochemical properties of GC and
the phospholipid bilayer (Buttgereit and Scheffold,
2002). Further, studies in which candidate molecules are
selected and characterized in depth are imperative to dis-
cern the specific regulatory mechanisms occurring in
chondrocytes.
Table 7: Growth factor transcripts vehicle in DEX-treated chondrocytes.
HUGO gene symbol Rank RMS RES
Fgf21 18968 -0.073 -0.508
Nrg3 19132 -0.077 -0.506
Fgf5 19190 -0.080 -0.499
Ereg 19507 -0.096 -0.502
Fgf7 19581 -0.102 -0.493
Gdf15 19660 -0.110 -0.483
Igf1 19679 -0.111 -0.469
Bmp5 19775 -0.124 -0.458
Nov 19848 -0.144 -0.443
Vegf 19877 -0.150 -0.425
Ptn 19885 -0.153 -0.406
Cxcl1 19928 -0.170 -0.386
Bdnf 19939 -0.176 -0.364
Inhba 19971 -0.204 -0.340
Gdf5 19973 -0.207 -0.313
Cxcl12 19978 -0.210 -0.287
Areg 19983 -0.219 -0.259
Hbegf 20006 -0.264 -0.226
Ngfb 20013 -0.287 -0.189
Lif 20024 -0.330 -0.148
Il11 20035 -0.404 -0.096
Il6 20043 -0.753 0.000
Rank = position of genes in the context of the ranked list of array genes
RMS = the ranked metric score
RES = the running enrichment scoreBMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Table 8: Micromass culture-derived gene sets are enriched in DEX-treated primary chondrocytes (d3 vs d15_2). I.
HUGO gene symbol Rank RMS RES
Itgbl1 32 0.391 0.015
Adrb2 54 0.308 0.026
Bst1 80 0.271 0.036
Gpx3 83 0.269 0.047
Myocd 90 0.259 0.058
Grk5 105 0.229 0.066
Ids 123 0.212 0.074
Ms4a6b 140 0.200 0.082
1810057c19rik 146 0.193 0.090
Igfbp2 149 0.190 0.097
Zfp36 218 0.159 0.100
Serpina3n 222 0.158 0.107
P2ry6 225 0.157 0.113
Adm 228 0.156 0.120
Crym 277 0.145 0.123
Ppap2a 303 0.139 0.128
Pycard 307 0.138 0.133
Kcns1 320 0.134 0.138
Cd80 321 0.134 0.144
Trim24 330 0.133 0.149
C1qtnf6 339 0.131 0.154
A330049m08rik 377 0.127 0.157
Adamts15 385 0.126 0.162
Elovl4 398 0.124 0.167
C1qa 402 0.124 0.172
Sox9 434 0.119 0.175
Htra3 455 0.116 0.179
Adam17 483 0.112 0.182
Mgll 493 0.112 0.186
Ibsp 507 0.110 0.190
C1qb 511 0.109 0.194
Bambi 516 0.109 0.199
Anxa4 551 0.105 0.201
Cd109 555 0.105 0.206
Nrk 559 0.104 0.210
Gstm1 619 0.099 0.211
Asb4 634 0.097 0.214
Pygl 654 0.095 0.217
Rasl11b 655 0.095 0.221
Cdc42ep4 674 0.093 0.224
Slc9a3r2 683 0.092 0.227
Lama1 688 0.092 0.231
Bb146404 707 0.091 0.234
Ai194308 724 0.090 0.237
Smn1 752 0.088 0.239
Alcam 772 0.087 0.242
Cst3 790 0.086 0.244
Pyp 847 0.083 0.245
2700017m01rik 870 0.082 0.247
Fgfr3 884 0.081 0.250
Mrpl34 912 0.080 0.252
C9orf46 972 0.077 0.252
Maf 981 0.077 0.255
8430420c20rik 1028 0.075 0.255
Gfm2 1030 0.075 0.259
Anxa6 1041 0.075 0.261
Isg20 1064 0.074 0.263
Auh 1068 0.074 0.266
Bsg 1100 0.072 0.267
Peg3 1179 0.070 0.266
Adam23 1208 0.069 0.268
Ezh1 1213 0.069 0.270
2810022l02rik 1214 0.069 0.273BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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0610011i04rik 1248 0.068 0.274
Pbx2 1257 0.067 0.277
Jup 1291 0.066 0.278
Zcwcc2 1301 0.066 0.280
Whsc2 1317 0.066 0.282
2410004l22rik 1344 0.065 0.283
Lmnb2 1388 0.064 0.284
Fndc1 1435 0.063 0.284
Rarres2 1460 0.062 0.285
Tap2 1512 0.061 0.285
Ctbs 1559 0.060 0.285
Jdp2 1574 0.059 0.287
Hck 1712 0.056 0.282
5031400m07rik 1792 0.054 0.281
Pkn1 1839 0.053 0.280
Dag1 1929 0.052 0.278
Fth1 1976 0.051 0.278
1110001e17rik 1979 0.051 0.280
Rbp4 1984 0.051 0.282
Pdcd6ip 2044 0.050 0.281
Siat7d 2050 0.050 0.283
Kcnd2 2074 0.050 0.284
2310004k06rik 2076 0.050 0.286
D19ertd678e 2106 0.049 0.286
Npdc1 2114 0.049 0.288
Fts 2116 0.049 0.290
Prickle1 2123 0.049 0.291
1110037f02rik 2171 0.048 0.291
Cdc42se1 2246 0.047 0.289
Chpt1 2261 0.047 0.290
Wwp2 2341 0.045 0.288
Dact1 2363 0.045 0.289
Rragd 2380 0.045 0.290
Irf5 2406 0.044 0.291
Nrbf2 2414 0.044 0.292
Cox4i2 2436 0.044 0.293
Bmp7 2456 0.044 0.294
1810008a18rik 2517 0.043 0.292
Asph 2533 0.043 0.293
Stat2 2550 0.042 0.294
Hoxa11 2560 0.042 0.296
Bax 2599 0.042 0.295
Sspn 2611 0.042 0.297
Ifngr2 2612 0.042 0.298
Glrx1 2672 0.041 0.297
Gba 2739 0.040 0.295
Fzd2 2759 0.040 0.296
Crtap 2772 0.040 0.297
Slc1a5 2786 0.040 0.298
Slco3a1 2831 0.039 0.297
3110040n11rik 2833 0.039 0.299
Tep1 2845 0.039 0.300
Fastk 2860 0.039 0.301
Tmed3 2869 0.038 0.302
Ephb4 2876 0.038 0.303
Asah2 2908 0.038 0.303
Pold4 2989 0.037 0.301
1110001a07rik 2995 0.037 0.302
Pcp4 3010 0.037 0.303
Mab21l2 3025 0.037 0.304
Rank = position of genes in the context of the ranked list of array genes
RMS = the ranked metric score
RES = the running enrichment score
Table 8: Micromass culture-derived gene sets are enriched in DEX-treated primary chondrocytes (d3 vs d15_2). I. (Continued)BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Table 9: Micromass culture-derived transcripts enriched in vehicle-treated primary chondrocytes (d3 vs d15_3/4). I.
HUGO gene symbol Rank RMS RES
Rabggtb 16734 -0.040 -0.271
Ube2e2 16759 -0.041 -0.270
Cd68 16769 -0.041 -0.269
H2-T23 16830 -0.041 -0.270
Derl1 16834 -0.041 -0.268
Smarcc1 16853 -0.041 -0.267
Srxn1 16856 -0.041 -0.266
Klf10 16868 -0.042 -0.264
Zfhx1b 16879 -0.042 -0.263
H2afy3 16929 -0.042 -0.264
Wisp2 16973 -0.042 -0.264
Tbl1xr1 16976 -0.042 -0.262
Ppp1r3c 16979 -0.042 -0.260
D11lgp2e 17036 -0.043 -0.261
Smpdl3b 17079 -0.043 -0.262
Dock2 17125 -0.044 -0.262
Purb 17127 -0.044 -0.260
Grn 17130 -0.044 -0.258
1110035l05rik 17139 -0.044 -0.257
Kiaa1008 17185 -0.045 -0.257
E430025l02rik 17195 -0.045 -0.256
Timm8a 17293 -0.046 -0.259
C130006e23 17307 -0.046 -0.257
Rbm10 17319 -0.046 -0.256
A230103n10rik 17347 -0.046 -0.255
Cd151 17401 -0.047 -0.256
Srf 17409 -0.047 -0.254
Cacna1s 17507 -0.048 -0.257
Ythdf1 17529 -0.048 -0.256
Ppp2r1b 17539 -0.048 -0.254
Tead2 17545 -0.048 -0.252
Igsf7 17590 -0.049 -0.252
Per3 17604 -0.049 -0.251
G1p2 17739 -0.050 -0.256
Slco2a1 17786 -0.051 -0.256
Coq7 17918 -0.053 -0.260
Rarb 17940 -0.053 -0.259
Lcp1 17954 -0.053 -0.257
Dnaja1 17987 -0.053 -0.256
Thoc3 17993 -0.054 -0.254
Cd44 18041 -0.054 -0.254
Slc41a1 18171 -0.056 -0.258
Kif11 18232 -0.057 -0.259
Hspa5bp1 18235 -0.057 -0.257
Ncf4 18290 -0.058 -0.257
Bub1b 18292 -0.058 -0.254
Cap2 18295 -0.058 -0.252
Aig1 18340 -0.059 -0.251
Rfc3 18361 -0.059 -0.250
Stmn1 18396 -0.060 -0.249
9130213b05rik 18408 -0.060 -0.247BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Tyms-Ps 18432 -0.060 -0.245
Timp3 18513 -0.062 -0.247
Tiparp 18564 -0.063 -0.247
Thbs4 18627 -0.064 -0.247
Wasf1 18652 -0.064 -0.245
Nupr1 18686 -0.065 -0.244
Ezh2 18706 -0.066 -0.242
Fbxl14 18709 -0.066 -0.239
Prim1 18780 -0.067 -0.240
Insig2 18805 -0.068 -0.238
B3gnt5 18858 -0.069 -0.238
Fam60a 18963 -0.072 -0.240
H2-M3 18972 -0.073 -0.237
Gja7 18974 -0.073 -0.234
Bex2 18987 -0.073 -0.231
Tk1 19043 -0.074 -0.231
1200015n20rik 19109 -0.076 -0.231
Clecsf5 19114 -0.077 -0.228
Ms4a7 19141 -0.078 -0.226
Cdca5 19163 -0.079 -0.223
C730042f17rik 19180 -0.079 -0.220
Trim25 19194 -0.080 -0.218
Efnb2 19207 -0.081 -0.215
Apex1 19236 -0.082 -0.212
Ddah2 19243 -0.082 -0.209
Bub1 19262 -0.083 -0.206
Nup43 19263 -0.083 -0.203
Rdh10 19270 -0.083 -0.199
2610201a13rik 19330 -0.086 -0.199
Rp2h 19406 -0.089 -0.198
Tnni1 19407 -0.089 -0.195
Myog 19423 -0.091 -0.191
Osmr 19486 -0.095 -0.190
Mmp9 19524 -0.097 -0.188
Tnnt1 19525 -0.098 -0.184
Fhod3 19528 -0.098 -0.179
D930038m13rik 19537 -0.099 -0.175
Nes 19567 -0.101 -0.172
Sbk1 19571 -0.102 -0.168
Dusp9 19594 -0.103 -0.165
Akr1b8 19622 -0.106 -0.161
Pdgfrb 19663 -0.110 -0.158
Tfrc 19667 -0.111 -0.154
Moxd1 19670 -0.111 -0.149
1810008k03rik 19681 -0.112 -0.145
Cpeb1 19710 -0.115 -0.141
6720475j19rik 19716 -0.116 -0.136
Ripk4 19718 -0.116 -0.131
Itga6 19756 -0.121 -0.127
Bmp5 19775 -0.124 -0.123
Lhx9 19776 -0.124 -0.117
Pkp2 19797 -0.129 -0.113
Chrna1 19808 -0.131 -0.108
Bhlhb2 19837 -0.142 -0.103
Table 9: Micromass culture-derived transcripts enriched in vehicle-treated primary chondrocytes (d3 vs d15_3/4). I. (Continued)BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Gp49a 19847 -0.144 -0.097
Clecsf10 19893 -0.155 -0.092
Gch1 19902 -0.159 -0.086
D0h4s114 19908 -0.161 -0.079
Cxcl1 19928 -0.170 -0.072
Ch25h 19946 -0.178 -0.065
Mkrn3 19988 -0.228 -0.057
Ptprc 20016 -0.297 -0.046
Car6 20017 -0.298 -0.032
Nr1d2 20031 -0.368 -0.017
Evi2a 20033 -0.393 0.001
Plxnc1 18075 -0.055 -0.286
Cilp2 18106 -0.055 -0.285
Brca1 18148 -0.056 -0.285
Litaf 18149 -0.056 -0.283
Bc027246 18154 -0.056 -0.281
6820424l24rik 18268 -0.057 -0.285
Hrb 18272 -0.057 -0.283
Nnat 18303 -0.058 -0.282
P2ry12 18329 -0.058 -0.282
Cdca4 18343 -0.059 -0.280
6030404e16rik 18367 -0.059 -0.279
Tfec 18429 -0.060 -0.280
Nfe2l2 18440 -0.060 -0.278
Gtf2h2 18467 -0.061 -0.277
4930469p12rik 18504 -0.062 -0.277
Cul4b 18535 -0.062 -0.276
H2afy2 18547 -0.063 -0.274
1190002n15rik 18582 -0.063 -0.274
B430218l07rik 18591 -0.063 -0.272
Rgs18 18607 -0.064 -0.270
Frk 18631 -0.064 -0.269
Slc6a9 18633 -0.064 -0.267
Tgfbr2 18687 -0.065 -0.267
Tia1 18802 -0.068 -0.270
Lgr5 18844 -0.068 -0.270
Sgpp1 18909 -0.071 -0.271
Matn2 18924 -0.071 -0.269
Sox11 18931 -0.071 -0.266
Hus1 18980 -0.073 -0.266
D930015e06rik 19028 -0.074 -0.266
Apob48r 19032 -0.074 -0.263
Av344025 19045 -0.074 -0.261
Eno2 19047 -0.074 -0.258
2610024e20rik 19053 -0.075 -0.256
Chd1l 19093 -0.076 -0.255
Emr1 19145 -0.078 -0.255
Rgs4 19200 -0.081 -0.254
D030028o16rik 19211 -0.081 -0.252
Kif2c 19216 -0.081 -0.249
Ccl3 19220 -0.081 -0.246
Trim30 19232 -0.082 -0.244
Qrsl1 19242 -0.082 -0.241
Nr3c1 19281 -0.083 -0.240
Table 9: Micromass culture-derived transcripts enriched in vehicle-treated primary chondrocytes (d3 vs d15_3/4). I. (Continued)BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Trip13 19282 -0.084 -0.237
Dna2l 19317 -0.085 -0.236
Tcf8 19335 -0.086 -0.233
Clecsf8 19341 -0.086 -0.230
Lyzs 19422 -0.090 -0.231
Palmd 19475 -0.095 -0.230
Tjp2 19487 -0.095 -0.227
D430019h16rik 19493 -0.096 -0.224
Sesn3 19501 -0.096 -0.221
Ereg 19507 -0.096 -0.218
Cx3cl1 19523 -0.097 -0.215
Fzd6 19529 -0.098 -0.211
Sod3 19564 -0.101 -0.209
Tnnt2 19580 -0.102 -0.206
Satb1 19599 -0.104 -0.203
Cd14 19606 -0.104 -0.200
Gbp2 19607 -0.104 -0.196
Tgfbi 19609 -0.105 -0.192
Chek1 19652 -0.109 -0.190
Tm4sf1 19653 -0.109 -0.186
Igf1 19679 -0.111 -0.183
Enpp1 19695 -0.113 -0.180
Slc15a3 19704 -0.114 -0.176
Pdpn 19725 -0.117 -0.173
Dkk1 19747 -0.119 -0.169
Slk 19759 -0.121 -0.166
Ankrd1 19794 -0.128 -0.163
Trp53bp1 19801 -0.129 -0.158
C79407 19804 -0.130 -0.153
2210010l05rik 19809 -0.131 -0.149
Eps8 19815 -0.133 -0.144
Dkk2 19862 -0.147 -0.141
Arhgap18 19863 -0.147 -0.136
Twist2 19878 -0.151 -0.131
Pcdha8 19915 -0.164 -0.126
Il4r 19926 -0.169 -0.121
Mdm1 19931 -0.172 -0.115
Phlda1 19957 -0.188 -0.109
Bhlhb5 19960 -0.192 -0.102
C130076o07rik 19964 -0.196 -0.095
5830411e10rik 19974 -0.207 -0.088
Ptpre 19989 -0.228 -0.080
Trib3 19990 -0.235 -0.071
9230117n10rik 19994 -0.241 -0.062
Pcdhb7 19998 -0.249 -0.053
Mmp3 20001 -0.252 -0.044
Cd34 20009 -0.274 -0.034
Thbd 20022 -0.310 -0.023
A830016g23rik 20023 -0.323 -0.011
Ahr 20028 -0.336 0.001
Rank = position of genes in the context of the ranked list of array genes
RMS = the ranked metric score
RES = the running enrichment score
Table 9: Micromass culture-derived transcripts enriched in vehicle-treated primary chondrocytes (d3 vs d15_3/4). I. (Continued)BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Heat map of top 100 probe sets determined by GSEA analysis Figure 5
Heat map of top 100 probe sets determined by GSEA analysis. GSEA-derived heat maps of the top 100 differentially 
expressed probe sets enriched with DEX or the vehicle control are shown (B). Expression profiles for all experimental repli-
cates are shown for each time point. Genes containing a putative GRE are shown in bold, and examples of genes that do not 
contain GREs but have been documented as targets of DEX regulation are depicted by bold gray lettering. Signal intensities are 
illustrated by varying shades of red (up-regulation) and blue (down-regulation).
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Conclusion
This study elucidates the downstream transcriptional
impact of pharmacological GC exposure on developing
chondrocytes. We have identified a small subset of tran-
scripts containing putative GREs in cartilage, but it
appears that GRE-independent or indirect mechanisms of
GC regulation also contribute to GC regulation in primary
chondrocyte monolayer cultures. In addition, traditional
microarray analysis methods and gene class testing point
to a dual role for pharmacological GC doses in chondro-
cytes. DEX acts in a gene class-specific manner in cartilage
in which it promotes the expression of ECM and meta-
bolic transcripts necessary for maintaining the chondro-
cyte phenotype while simultaneously downregulating
cytokines and growth factors which stimulate the cartilage
to bone transition. Understanding the implications of
gene expression changes and integrating them into the
network of molecules controlling cartilage development
continues to be challenging, but robust analytical meth-
ods will prove to be useful in constructing the networks of
gene interactions and understanding the complex nature
of GC signaling in the skeleton. The ultimate objective of
this study will be to translate these findings into more effi-
cacious therapeutic GCs.
Methods
Animals and Materials
Timed-pregnant CD1 mice were purchased from Charles
River Laboratories at embryonic day E15.5 mice (E15.5).
Dexamethasone was obtained from Calbiochem and
reconstituted in Dimethyl sulfoxide (DMSO, vehicle)
according to the manufacturer's instructions. Cell culture
materials and general chemicals were obtained from Inv-
itrogen, Sigma or VWR unless otherwise stated.
Primary cell culture and dexamethasone-treatment
Tibiae, femurs and humeri were isolated from E15.5
mouse embryos and placed in α-MEM media (Invitrogen)
containing 0.2% Bovine Serum Albumin (BSA), 1 mM β-
glycerophosphate, 0.05 mg/ml ascorbic acid and penicil-
lin/streptomycin and incubated at 37°C in a humidified
5% CO2  incubator overnight. The following morning
media was removed and the bones placed in 4 ml of
0.25% trypsin-EDTA (Invitrogen) for 15 min at 37°C.
Trypsin was subsequently replaced with 1 mg/ml colla-
genase P (Roche) in DMEM/10% fetal bovine serum (Inv-
itrogen), and cells were incubated at 37°C with rotation
at 100 rpm for 90 min. Following digestion, the cell sus-
pension was centrifuged for 5 min at 1000 rpm, and the
collagenase containing supernatant was decanted.
Chondrocytes were resuspended in media containing 2:3
DMEM:F12, 10% fetal bovine serum, 0.5 mM L-
glutamine, and penicillin/streptomycin (25 units/ml).
Cells were seeded in 6-well NUNC plates at a density of
2.5 × 104 cells per ml and incubated overnight. Primary
monolayer chondrocytes were treated with 10-7 M dexam-
ethasone (DEX) or the DMSO control (vehicle) diluted in
fresh media supplemented with 0.25 mM ascorbic acid
(Sigma) and 1 mM β-glycerophosphate (Sigma) and incu-
bated for up to 24 hrs. Micromass cultures were com-
pleted as previously described [50].
Cell counting studies
Chondrocytes were isolated and seeded in 24-well NUNC
plates (Nunc Inc.) at a density of 16 000 cells/cm2. Cells
were cultured, treated and enzymatically digested as
described with some modifications. Collagenase diges-
tion occurred for 5 minutes followed by mechanical diges-
tion to liberate cells from the ECM. Cells were counted
with a hemocytometer in triplicate with a minimum of 3
individual wells per treatment and three independent cell
isolations.
RNA isolations and quantitative real-time PCR
All RNA protocols were completed as previously outlined
[50]. Total RNA was isolated at 6 hrs and 24 hrs after treat-
ment using the RNeasy mini extraction kit (Qiagen)
according to the manufacturer's instructions. RNA quan-
tity and integrity was assessed using the Bioanalyzer 2000
system (Agilent). Quantitative real-time polymerase chain
reaction (qRT-PCR) amplification was completed using
the ABI Prism 7900 Sequence Detection System (Applied
Biosystems). Triplicate reactions were executed for each
sample of each of three independent trials. The TaqMan
one-step master mix kit (Applied Biosystems) with gene-
specific target primers and probes were used for amplifica-
tion. The collagen X (Col10a1) probe and primer set (for-
ward primer 5'-ACGCCTACGATGTACACGTATGA-3',
reverse primer 5'-ACTCCCTGAAGCCTGATCCA-3', 6-
FAM-5'-AGTACAGCAAAGGCTAC-MGBNFQ) was
designed with PrimerDesigner 2.0 software (Applied Bio-
systems) [79]. TaqMan GAPDH control reagents for
house-keeping gene glyceraldehyde-3-phosphate dehy-
drogenase (Gapdh, forward primer 5'-GAAGGTGAAG-
GTCGGAGTC; reverse primer 5'-
GAAGATGGTGATGGGATTTC; probe JOE-CAAGCTTC-
CCGTTCTCAGCC-TAMRA) was used as an internal
amplification control. Probes for Indian hedgehog (Ihh),
Tissue inhibitor of matrix metalloproteinase 4 (Timp4),
Cyclin-dependent kinase inhibitor 1C (Cdkn1c, p57),
Integrin beta like 1 protein (Itgbl1), GC receptor (Nr3c1),
Integrin beta 1 (Itgb1) and Kruppel-like factor 15 (Klf15)
were assayed using the TaqMan® gene expression assays in
accordance with the manufacturers directions. Amplified
transcripts were quantified using the standard curve
method, and the relative transcript abundance was deter-
mined by calculating the quotient of the gene of interest
and equivalent Gapdh values.BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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Microarray analysis
Total RNA was extracted from control and DEX-treated
cultures at 6 hr and 24 hr following treatment, in three
independent experiments. RNA integrity and quantity was
assessed using the Agilent 2000 Bioanalyzer system, and
RNA samples were subsequently hybridized to the MOE
430 2.0 mouse chip from Affymetrix© containing 45 101
probe sets as described [50]. Bioanalysis, microarray
hybridization, scanning and preliminary MAS 5.0 nor-
malizations were completed at the London Regional
Genomics Facility. Data were deposited in the GEO data-
base (NCBI; accession number GSE7683).
Data normalization
Microarray data were pre-processed using the GC-RMA
algorithm in Genespring GX*. Expression values were fur-
ther filtered by retaining only those probe sets with
expression values of at least 50 in at least 25% of all con-
ditions, thus generating a list of 22 091 probe sets. To
assess differential gene expression between treatments at
both the 6 and 24 hr time points, a Welch ANOVA test
with a p-value cut-off of 0.01 and a 5% false discovery rate
(FDR) reduced the data to 1158 probe sets. Subsequent
1.5-, 5- and 10-fold change filters produced lists of 162,
21 and 7 probe sets for the 6 hr time point and 399, 53
and 19 probe sets for the 24 hr time point, respectively.
The same data set was normalized in parallel using Robust
Multichip Analysis using RMAEXPRESS software v.0.4.1
developed by B. Bolstad, University of California, Berke-
ley [110]. Background adjustment and quantile normali-
zation parameters were selected for data processing.
Logarithmically transformed expression values were used
to implement Gene Set Enrichment Analysis (GSEA).
Gene set enrichment analysis (GSEA)
The GSEA algorithm was implemented with GSEA v2.0
software [51,52]. Ranked expression lists were derived
from RMAEXPRESS and GeneSpring GX® 7.3.1. Briefly, the
GSEA algorithm ranks all array genes according to their
expression under each experimental condition. The result-
ing ranked metric score (RMS) is therefore a function of
the correlation between a gene's signal intensity, the
experimental conditions in question and all other genes
in the data set. An enrichment score (ES) is then calculated
for an a priori gene list or gene set that is associated with
a particular molecular classification. In our analysis, gene
sets were created from different functional groupings,
molecular classifications, tissues, and other microarray
screens. A Ranked enrichment score (RES) which deter-
mines the extent to which a given gene from a gene set is
represented at the extremes of the ranked gene list is then
calculated. Specifically, this value is obtained by walking
along the ranked list using a cumulative sum statistic
which increases when a member of a particular gene set is
found in the ranked gene list and is coordinately penal-
ized when it does not appear in the gene set. A null distri-
bution of ES is subsequently generated by permutation
filtering to evaluate the statistical significance of the
observed RES values. Permutation filtering randomly
assigns the experimental conditions or class labels (i.e.,
DEX versus vehicle) to the different microarray samples.
After this procedure has been repeated for each gene set,
the ES are normalized (NES) to account for differences in
gene set size. The false discovery rate (FDR) is then calcu-
lated relative to the NES values to determine the false-pos-
itive rate. Significant FDR and p-values were less than 25%
and 0.001, respectively in accordance with GSEA recom-
mendations.
Gene set creation
Gene sets were generated using the probe set search tool
and the molecular function class of Gene Ontology anno-
tations in GeneSpring GX. Additional gene sets were cre-
ated using lists from pairwise comparisons between day 3
and 15 of a previously generated micromass data set
(James et al., 2005), and publications that identified DEX
target genes in other cartilage array screens, other tissue
types and experimental systems. A total of 2119 probe sets
showing a minimum 1.5-fold change in gene expression
were used in the analysis. Probe set redundancy was elim-
inated in all gene sets using the CollapseDataset function
in the GSEA program. All probe set identifiers were assim-
ilated to the Human Genome Organization (HUGO)
annotations. Probe sets lacking corresponding HUGO
annotations were excluded from the analysis. Default
parameters were used to execute the analysis and median
values taken to represent the range of duplicated probe
sets for a given gene. A total of 77 user-defined gene sets
were generated from GeneSpring derived Gene Ontology
annotations for various molecular classifications and
probe sets of differentially expressed genes between days
3 and 15 of micromass culture (James et al., 2005).
Glucocorticoid response element (GRE) analysis
Putative GRE were identified with the GenespringGX
mouse genome9999 application which allows sequences
up to 9999 bp upstream of the transcriptional start sites of
all annotated MOE4302.0 transcripts to be interrogated
for transcription factor binding sites. The GR consensus
sequence GGTACAnnntgttCT [111] was queried from 10
bp to 10 000 bp upstream of the transcriptional start sites
of available probe sets. The GRE consensus sequence was
screened against 10 748 probe sets derived from the list of
22 091 reliably expressed probe sets exhibiting homology
to upstream regulatory regions annotated in the program.
Only exact matches were retained for subsequent analyses
out a total of 1,073,741,824 tests.BMC Genomics 2007, 8:205 http://www.biomedcentral.com/1471-2164/8/205
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